Zevra Therapeutics (NASDAQ:ZVRA) Announces Earnings Results, Misses Estimates By $0.28 EPS

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28), Zacks reports. The company had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

Zevra Therapeutics Stock Up 1.8 %

ZVRA traded up $0.14 during trading on Friday, hitting $8.08. The company had a trading volume of 23,641 shares, compared to its average volume of 410,123. The company has a market capitalization of $431.28 million, a PE ratio of -4.08 and a beta of 1.98. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76. The firm's 50-day moving average price is $7.93 and its 200 day moving average price is $8.14. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday. Guggenheim raised their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday. Canaccord Genuity Group raised their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of Zevra Therapeutics in a research report on Wednesday. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $22.14.

Remove Ads

Insider Buying and Selling at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 61,273 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at $1,745,391.60. The trade was a 21.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Joshua Schafer sold 10,500 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares in the company, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 85,773 shares of company stock worth $674,176. Insiders own 2.40% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.